
    
      In Phase 1A, hormone naive and hormone independent patients are enrolled in a 1:1 ratio. All
      patients receive intradermal injections of the PSA/IL-2/GM-CSF induction vaccine at Weeks 1,
      2, 3, 7, 11 and 15.

      In Phase 1B, which will be initiated after Phase 1A, will first receive the induction vaccine
      (PSA/IL-2/GM-CSF) according to the same schedule as patients in Phase 1A. Then, in eligible
      Phase 1B patients, following the induction vaccine regimen, alternating maintenance
      vaccination will be administered as follows: at Weeks 23, 31, and 39, IL-2 alone will be
      administered; at Weeks 27, 35, and 43, the complete vaccine (PSA/IL-2/GM-CSF) will be
      administered.
    
  